论文部分内容阅读
奥地利维也纳消息:据最近两项研究报道,在经尿道切除术后膀胱内免疫疗法极大地减少了表层膀胱癌的复发率。在美国泌尿学协会纽约地区的第85届年会上介绍了这两项研究。在纽约城的纪念SloanKettering癌症中心(MSKCC)进行的一项研究中,兔疫治疗剂是卡介苗(BCG)。在埃及的另一项研究使用了BCG和一种新药——麦芽糖四栋榈酸(MTP)。埃及曼苏拉大学泌尿和肾病学中心的ElHousseiny Ibrahiem医师介绍了埃及的试验。15名有表层转变细胞膀胱癌复发史的病人
Vienna, Austria: According to two recent studies, intravesical immunotherapy after transurethral resection has greatly reduced the recurrence rate of superficial bladder cancer. Both studies were presented at the 85th Annual Meeting of the American Urological Association in New York. In a study conducted at the Memorial SloanKettering Cancer Center (MSKCC) in New York City, the immunization was BCG. Another study in Egypt used BCG and a new drug, maltose tetra-palmitate (MTP). El Housseiny Ibrahiem, MD, of the Urology and Nephrology Center at Mansoura University in Egypt, introduced the Egyptian experiment. 15 patients with superficial changes in the history of bladder cancer recurrence